The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart.
The main question it aims to answer is whether MRgART affects the heart differently than LINAC.
Participants will:
* Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires
Age > 18 years at the time of consent.
Dosimetric eligibility criteria met using endpoints from QUANTEC (>10% of heart receives > 25 Gy) as determined through rapid auto-planning
Stage IIB, IIIA, IIIB, IIIC, or IV non-operable non-small cell lung cancer
Limited stage small cell lung cancer, once daily treatment (excluding twice per day fractionation schemes). Stage I-III N0-2 disease esophageal/esophagogastric cancer
Definitive clinical or radiologic evidence of metastatic disease with life expectancy <12 months
Prior thoracic radiotherapy significantly overlapping the heart region
Contraindications to MRI
Severe, active co-morbidity defined as follows: New York Heart Association Functional Classification III/IV are not eligible.
University of Wisconsin, Madison
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator